Supplementary Conditional Placing for £60,000
THIS ANNOUNCEMENT (THE "ANNOUNCEMENT") AND THE INFORMATION CONTAINED IN IT, IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES OR THE DISTRICT OF COLUMBIA (COLLECTIVELY, THE "UNITED STATES"), AUSTRALIA, CANADA, THE REPUBLIC OF SOUTH AFRICA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH PUBLICATION, RELEASE OR DISTRIBUTION WOULD BE UNLAWFUL.
FURTHER, THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND IS NOT AN OFFER OF SECURITIES IN ANY JURISDICTION.
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION.
1 August 2024
Aptamer Group plc
("Aptamer Group", "APTA" or the "Company")
Supplementary Conditional Placing for £60,000
Aptamer Group (AIM:APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, announces that, in addition to the Placing and Subscription announced on 24 July 2024 (the "Fundraising"), it has agreed to issue a further 30,000,000 New Ordinary Shares ("Supplementary Placing Shares") at the same issue price of 0.2p per share, raising £60,000 (before expenses), which will be for working capital purposes.
This additional sum has arisen due to a reconciliation error by the Company's broker, Turner Pope Investments (TPI) Ltd ("Turner Pope"), relating to client orders received in the Fundraising. Turner Pope noticed this matter yesterday and informed the Company and the Board has agreed to issue the Supplementary Placing Shares.
Notwithstanding the circumstances under which the proposed issue of the Supplementary Placing Shares has arisen, they will not form part of the Fundraising and will be issued as a separate tranche. Both the conditional element of the Fundraising and the Supplementary Placing Shares are subject to shareholder approval of the resolutions at the Company's General Meeting, which is scheduled for 13 August 2024.
Subject to the passing of the resolutions at the General Meeting, admission of the Supplementary Placing Shares is expected to become effective and dealings are expected to commence at 8.00 a.m. on 14 August 2024 ("Admission").
Total Voting Rights
Immediately following Admission the Company will have 1,920,343,673 ordinary shares of £0.001 each in issue.
The Company does not hold any shares in treasury and all of the Ordinary Shares have equal voting rights. Therefore, the figures above represent the total voting rights in the Company and may be used by shareholders as the denominator for the calculations by which they can determine if they are required to notify their interest in, or a change to their interest in the Company under the Rules.
- ENDS -
For further information, please contact:
|
Aptamer Group plc Dr Arron Tolley |
+44 (0) 1904 217 404 |
|
SPARK Advisory Partners Limited - Nominated Adviser Andrew Emmott / Adam Dawes |
+44 (0) 20 3368 3550 |
|
Turner Pope Investments (TPI) Ltd - Broker James Pope / Andrew Thacker |
+44 (0) 20 3657 0050 |
Unless otherwise indicated, capitalised terms in this announcement have the meaning given to them in this announcement (including the definitions section included in the Appendix).
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018.
About Aptamer Group plc
Aptamer Group develops custom affinity binders through its proprietary Optimer® platform to enable new approaches in therapeutics, diagnostics, and research applications. The Company strives to deliver transformational solutions that meet the needs of life science researchers and developers.
Optimer binders are oligonucleotide affinity ligands that can function as an antibody alternative. The global affinity ligand market is currently worth over $170 billion.
Aptamer has successfully delivered projects for a range of global pharma companies, diagnostic development companies, and research institutes, covering multiple application areas with the objective of establishing royalty-bearing licenses.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 1 day ago Savannah Energy
- 1 day ago Buccaneer Energy PLC
- 1 day ago Savannah Energy
- 1 day ago Carclo
- 1 day ago Schroder Japan Growth Fund